FDA Proposes QbR for New Drugs to Level the Playing Field for CMC Reviews
This article was originally published in The Gold Sheet
Executive Summary
FDA has proposed to expand the use of question-based review, or QbR, to new drugs as part of its efforts to harmonize new and generic drug chemistry reviews. This reflects the agency’s latest efforts to improve the quality of brand and generic drugs by levying “equal expectations” for both.
You may also be interested in...
FDA Developing Initiatives to Improve Quality of Drug Master Files
The quality of DMFs is expected to improve thanks to a soon to be released question- based review system for DMF holders as well a recently issued draft guidance calling for new procedures for reviewing master files called “completeness assessments,” said a pharmaceutical industry official who was a former team leader in FDA’s Office of Generic Drugs.
FDA Warns Generics Firms About January QbD Deadline for ANDAs
Come January, if there is no quality target product profile (QTPP) in an abbreviated new drug application (ANDA), FDA might not file it, agency officials told a Generic Pharmaceutical Association workshop. Even though quality by design (QbD) remains optional for brand drugs, it will be expected for generics, said Office of Generic Drugs representatives who went on to outline pending question-based-review (QbR) revisions designed to elicit QbD information.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”